Lyell Immunopharma (LYEL) Assets Average (2021 - 2026)

Lyell Immunopharma's Assets Average history runs 6 years deep, the most recent figure standing at $345.3 million for Q1 2026.

• In Q1 2026, Assets Average fell 24.98% year-over-year to $345.3 million; the TTM figure through Mar 2026 stood at $345.3 million (down 24.98% YoY), while the FY2025 annual figure was $415.5 million, down 33.04% from the prior year.
• Assets Average came in at $345.3 million for Q1 2026 at Lyell Immunopharma, down from $374.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.1 billion in Q1 2022 to a low of $345.3 million in Q1 2026.
• A 5-year average of $707.7 million and a median of $722.1 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average retreated 17.34% in 2023 and slumped 39.54% in 2025, its largest moves.
• Lyell Immunopharma's Assets Average stood at $957.4 million in 2022, then decreased by 19.31% to $772.5 million in 2023, then fell by 28.15% to $555.0 million in 2024, then tumbled by 32.62% to $374.0 million in 2025, then decreased by 7.67% to $345.3 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $345.3 million, $374.0 million, and $396.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison